Hematologic Oncology Update

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:
Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)
Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)
Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)

CME information and select publications

Featuring perspectives from Prof John Seymour, including the following topics:
Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)
Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)
First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)

CME information and select publications

Featuring perspectives from Dr William G Wierda, including the following topics:
Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)
Sequencing Road Map (12:39)
Key Datasets — Pirtobrutinib (21:08)
Investigator Survey (34:09)
Chimeric Antigen Receptor T-Cell Therapy (45:08)
Other Novel Therapy Approaches (49:58)
EHA 2026 (54:45)

CME information and select publications

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:
Introduction: Lymphoma Survivorship (0:00)
Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)
Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14)

CME information and select publications

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:
Introduction (00:00)
Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)
Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)
Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)
ASCO and EHA 2026 (46:37)

CME information and select publications